Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage i lung adenocarcinoma

Cancer Research

Volumn 73, Issue 13, 2013, Pages 3821-3832

  Akagi, Ichiro ^a,b   Okayama, Hirokazu ^a,d   Schetter, Aaron J ^a   Robles, Ana I ^a   Kohno, Takashi ^c   Bowman, Elise D ^a   Kazandjian, Dickran ^a   Welsh, Judith A ^a   Oue, Naohide ^e   Saito, Motonobu ^d   Miyashita, Masao ^b   Uchida, Eiji ^b   Takizawa, Toshihiro ^b   Takenoshita, Seiichi ^d   Skaug, Vidar ^f   Mollerup, Steen ^f   Haugen, Aage ^f   Yokota, Jun ^c   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; EXPORTIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 21; PROTEIN DLC1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CA9 GENE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CCT3 GENE; CLASSIFIER; COHORT ANALYSIS; CONTROLLED STUDY; DLC1 GENE; ETHNIC DIFFERENCE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HIF1A GENE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; JAPAN; LUNG ADENOCARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; NORWAY; NUCLEOTIDE SEQUENCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UNITED STATES; VALIDATION PROCESS; XPO1 GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; KARYOPHERINS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84880071253     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0031     Document Type: Article

References (55)

1. http://www.nccn.org.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479-85.
3. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007;13: 73-7.
4. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33: 49-54.
5. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5: 845-56.
6. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350: 1828-37.
7. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8: 816-24.
8. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-44.
9. Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004;22: 811-9.
10. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I nonsmall cell lung cancer. PLoS Med 2006;3: e467.
11. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007;117: 3436-44.
12. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14: 7397-404.
13. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66: 7466-72.
14. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A fivegene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356: 11-20.
15. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009;27: 2793-9.
16. Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, et al. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS ONE 2010;5: e12222.
17. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011;17: 1875-82.
18. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010; 102: 464-74.
19. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes up-regulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012;72: 100-11.
20. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98: 13790-5.
21. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14: 822-7.
22. http://www3.cancer.gov/intra/lhc/Supplemental-Data-and-coding-CR.zip.
23. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNAprocessing patterns in tissues, cell lines, and tumors. RNA 2008;14: 35-42.
24. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350: 1713-21.
25. Roselli M, Mariotti S, Ferroni P, Laudisi A, Mineo D, Pompeo E, et al. Postsurgical chemotherapy in stage IB non small cell lung cancer: long-term survival in a randomized study. Int J Cancer 2006;119: 955-60.
26. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352: 2589-97.
27. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7: 719-27.
28. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for nonsmall cell lung cancer-how to handle stage I disease. Oncologist 2007;12: 331-7.
29. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85: 881-90.
30. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60: 4693-6.
31. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59: 5830-5.
32. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61: 2911-6.
33. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25: 5562-9.
34. Bussing I, Yang JS, Lai EC, Grosshans H. The nuclear export receptor XPO-1 supports primary miRNA processing in C. elegans and Drosophila. EMBO J 2010;29: 1830-9.
35. Castanotto D, Lingeman R, Riggs AD, Rossi JJ. CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A 2009;106: 21655-9.
36. Brodie KM, Henderson BR. Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem 2012;287: 7701-16.
37. Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A 2008;105: 16958-63.
38. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18: 7288-93.
39. Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004;23: 1405-11.
40. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, et al. DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007;11: 1185-207.
41. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 2010;8: 86.
42. Black DM, Solomon E. The search for the familial breast/ovarian cancer gene. Trends Genet 1993;9: 22-6.
43. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96: 1659-68.
44. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2: e1129.
45. Saha T, Rih JK, Roy R, Ballal R, Rosen EM. Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 2010;285: 19092-105.
46. Silver DP, Livingston DM. Mechanisms of BRCA1 tumor suppression. Cancer Discov 2012;2: 679-84.
47. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319: 1352-5.
48. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103: 2257-61.
49. Medina PP, Nolde M, Slack FJ.OncomiR addiction in an in vivomodel of microRNA-21-induced pre-B-cell lymphoma. Nature 2010;467: 86-90.
50. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18: 282-93.
51. Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J 2012;18: 244-52.
52. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144: 646-74.
53. Zhang X, Ng WL, Wang P, Tian L, Werner E, Wang H, et al. MicroRNA- 21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFalpha. Cancer Res 2012;72: 4707-13.
54. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009;106: 12085-90.
55. Croce CM. miRNAs in the spotlight: understanding cancer gene dependency. Nat Med 2011;17: 935-6.